Press Room

5th European Conference on Pharmaceutics

Start
Tuesday, March 25, 2025 - 16:20
End
Tuesday, March 25, 2025 - 17:00
Location: Porto, Portugal
Hovione session at the 5th European Conference on Pharmaceuticals | Hovione

Interested in innovative dosage forms and advanced therapeutic technologies? Porto is hosting renowned industry experts, academia and the next generation of researchers to share the latest advances and Cláudia Pina Costa, proudly representing Hovione’s young scientists, will join the conversation with an oral session on “Key parameters for nasal dry powders performance characterization”. 

Can’t make it to Porto to attend the 5th European Conference on Pharmaceutics? Connect with our Inhalation and Nasal experts at RDD Europe next May. 

Learn more about our Inhalation and Nasal offering.

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026